A randomized, controlled, open-label, phase 2 study of cemiplimab �� RP1 in patients with advanced cutaneous squamous cell carcinoma (CERPASS).

Citation

• Haydon, A. M., Khushalani, N. I., Robert, C., Brungs, D., Collichio, F. A., Colevas, A. D., . . . Migden, M. R. (2022). A randomized, controlled, open-label, phase 2 study of cemiplimab �� RP1 in patients with advanced cutaneous squamous cell carcinoma (CERPASS).. Journal of Clinical Oncology, 40(16_suppl), tps9593. doi:10.1200/jco.2022.40.16_suppl.tps9593

Digital Object Identifier (doi)

• 10.1200/jco.2022.40.16_suppl.tps9593

Web Of Science Accession Number

Start Page

• tps9593

End Page

• tps9593

Volume

• 40

Issue

• 16_suppl

Place Of Publication

Abstract

UOW Authors

•   Brungs, Daniel

Publication Date

• 2022

Publisher

• American Society of Clinical Oncology (ASCO) 

Published In

• Journal of Clinical Oncology  Journal

Citation

• Haydon, A. M., Khushalani, N. I., Robert, C., Brungs, D., Collichio, F. A., Colevas, A. D., . . . Migden, M. R. (2022). A randomized, controlled, open-label, phase 2 study of cemiplimab �� RP1 in patients with advanced cutaneous squamous cell carcinoma (CERPASS).. Journal of Clinical Oncology, 40(16_suppl), tps9593. doi:10.1200/jco.2022.40.16_suppl.tps9593

Digital Object Identifier (doi)

• 10.1200/jco.2022.40.16_suppl.tps9593

Web Of Science Accession Number

Start Page

• tps9593

End Page

• tps9593

Volume

• 40

Issue

• 16_suppl

Place Of Publication